Lester Murray Antman dba SimplyRich Increases Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Lester Murray Antman dba SimplyRich boosted its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 465.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 37,423 shares of the company’s stock after acquiring an additional 30,806 shares during the quarter. Lester Murray Antman dba SimplyRich’s holdings in Dr. Reddy’s Laboratories were worth $590,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. lifted its position in shares of Dr. Reddy’s Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares in the last quarter. State Street Corp raised its stake in Dr. Reddy’s Laboratories by 1.9% in the 3rd quarter. State Street Corp now owns 909,905 shares of the company’s stock valued at $72,292,000 after purchasing an additional 16,641 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in Dr. Reddy’s Laboratories by 59.4% in the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after purchasing an additional 183,146 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Dr. Reddy’s Laboratories by 30.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock worth $32,530,000 after purchasing an additional 96,339 shares during the last quarter. Finally, Artemis Investment Management LLP boosted its stake in Dr. Reddy’s Laboratories by 398.3% during the 4th quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock worth $4,666,000 after purchasing an additional 236,224 shares during the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Barclays cut their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Finally, Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Stock Up 0.0 %

NYSE RDY opened at $13.82 on Wednesday. The business’s fifty day simple moving average is $14.76 and its 200-day simple moving average is $15.34. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The firm has a market cap of $11.53 billion, a PE ratio of 22.00 and a beta of 0.50. Dr. Reddy’s Laboratories Limited has a 52 week low of $13.36 and a 52 week high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, equities analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.